Adma Biologics, Inc. (ADMA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Adma Biologics reported revenue of $510.2M, up 19.6% from $426.5M the year before. Net income was $146.9M (a 28.8% net margin), or $0.60 per diluted share. Gross margin was 57.4% and operating margin was 37.5%. Operating activities generated $50.4M of cash, leaving $27.8M of free cash flow. At fiscal year end, Adma Biologics held $624.2M in total assets against $146.9M in total liabilities, including $87.6M of cash and equivalents.
Open the full interactive Adma Biologics financials → Quarterly statements, key ratios, valuation history and price charts.
Adma Biologics Key Stats
| Share Price | $10.31 |
|---|---|
| Market Cap | $2.37B |
| P/E Ratio | 17.2 |
| Revenue YoY Growth | +19.6% |
| 52-Week Range | $7.60 – $20.38 |
| Shares Outstanding | 228.2 million (basic, 2026 Q2) |
Adma Biologics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Gross Profit | -$19.1M | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| Operating Income | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| Pre-Tax Income | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $125.7M | $182.7M |
| Income Tax | $0 | $0 | $0 | $0 | -$72.0M | $35.7M |
| Net Income | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| Diluted EPS | -$0.88 | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
Adma Biologics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $134.2M | $139.2M | $114.5M | $124.4M |
| Net Income | $36.4M | $49.4M | $45.3M | $37.8M |
| Diluted EPS | $0.15 | $0.20 | $0.19 | $0.16 |
Adma Biologics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $55.9M | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Current Assets | $153.7M | $208.7M | $270.4M | $257.0M | $331.4M | $466.5M |
| Total Assets | $207.7M | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M |
| Current Liabilities | $19.9M | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M |
| Total Long-Term Debt | $100.0M | $94.9M | $142.8M | $130.6M | $72.3M | $72.1M |
| Total Liabilities | $119.4M | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M |
| Shareholders' Equity | $88.2M | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
Adma Biologics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$102.0M | -$112.4M | -$59.5M | $8.8M | $118.7M | $50.4M |
| Cash From Investing | -$12.7M | -$13.5M | -$13.9M | -$5.0M | -$8.6M | -$21.9M |
| Cash From Financing | $143.9M | $121.0M | $108.9M | -$39.0M | -$58.3M | -$44.0M |
| Free Cash Flow | -$114.7M | -$125.9M | -$73.4M | $4.0M | $110.4M | $27.8M |
Figures from Adma Biologics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Adma Biologics financials page for every line item.
Adma Biologics Company Profile
| Ticker | ADMA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Ramsey, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001368514 |
Frequently Asked Questions
What was Adma Biologics' revenue in fiscal 2025?
Adma Biologics (ADMA) reported revenue of $510.2M for fiscal 2025.
What is Adma Biologics' annual revenue history?
Adma Biologics' annual revenue by fiscal year: 2020: $42.2M; 2021: $80.9M; 2022: $154.1M; 2023: $258.2M; 2024: $426.5M; 2025: $510.2M.
What was Adma Biologics' net income in fiscal 2025?
Adma Biologics reported net income of $146.9M for fiscal 2025.
What was Adma Biologics' earnings per share (EPS) in fiscal 2025?
Adma Biologics' diluted EPS was $0.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Adma Biologics generate in fiscal 2025?
Adma Biologics generated $27.8M of free cash flow in fiscal 2025.
What was Adma Biologics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Adma Biologics reported revenue of $124.4M.
How much debt does Adma Biologics have?
Adma Biologics reported $72.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Adma Biologics are outstanding?
Adma Biologics reported a weighted average of 228.2 million basic shares outstanding in 2026 Q2.
What is Adma Biologics' market cap?
Based on its latest closing price, Adma Biologics (ADMA) has a market capitalization of about $2.37B.
When does Adma Biologics' fiscal year end?
Adma Biologics' fiscal year end, as registered with the SEC, is December 31.
Where is Adma Biologics headquartered?
Adma Biologics lists its business address in Ramsey, New Jersey in its SEC filings.
Adma Biologics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →